Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines

Wu,Feng  Ying; Fan,Jiang; Tang,Liang; Zhao,Yin  Min; Zhou,Cai  Cun

doi:10.3892/ol.2013.1358

Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines

Authors:
- Feng Ying Wu
- Jiang Fan
- Liang Tang
- Yin Min Zhao
- Cai Cun Zhou
View Affiliations

Affiliations: Central Laboratory of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China, Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China
Published online on: May 21, 2013 https://doi.org/10.3892/ol.2013.1358
Pages: 91-95

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokines and their receptors have been shown to play a vital role in lung cancer progression. D6 is an atypical chemokine receptor which is able to internalize and degrade chemokines. To investigate the potential role of D6 in lung cancer, we established D6-overexpressing A549 lung cancer cell lines by the transfection of human D6 cDNA. Results showed that D6 inhibited the proliferation of cancer cells in vitro and tumorigenesis in vivo. We also determined chemokine levels in the supernatant and showed that a number of chemokines (CCL2/4/5) had significantly decreased protein levels in D6-overexpressing cells compared with the controls, whereas no significant changes in mRNA expression levels of these chemokines were detected. The cell cycle distribution and expression of certain growth factors and their receptors did not change in the D6-overexpressing cells compared with parental cells. Thus, our results suggest that D6 is a negative regulator of growth in lung cancer, mainly by the sequestration of specific chemokines.

View Figures

View References

1.	Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010. View Article : Google Scholar
2.	Zlotnik A: Chemokines and cancer. Int J Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Ben-Baruch A: The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25:357–371. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Comerford I, Litchfield W, Harata-Lee Y, Nibbs RJ and McColl SR: Regulation of chemotactic networks by ‘atypical’ receptors. Bioessays. 29:237–247. 2007.
5.	Feng LY, Ou ZL, Wu FY, Shen ZZ and Shao ZM: Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res. 15:2962–2970. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Wang J, Ou ZL, Hou YF, et al: Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene. 25:7201–7211. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Wu FY, Ou ZL, Feng LY, et al: Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res. 6:1276–1288. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Addison CL, Belperio JA, Burdick MD and Strieter RM: Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer. 4:282004. View Article : Google Scholar : PubMed/NCBI
9.	Ramezani A and Hawley RG: Overview of the HIV-1 Lentiviral Vector System. Curr Protoc Mol Biol Chapter 16: Unit 16.21,. 2002, View Article : Google Scholar
10.	Kruizinga RC, Bestebroer J, Berghuis P, et al: Role of chemokines and their receptors in cancer. Curr Pharm Des. 15:3396–3416. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Wong D and Korz W: Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin Cancer Res. 14:7975–7980. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Graham GJ and McKimmie CS: Chemokine scavenging by D6: a movable feast? Trends Immunol. 27:381–386. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Locati M, Torre YM, Galliera E, et al: Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine Growth Factor Rev. 16:679–686. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Nibbs RJ, Gilchrist DS, King V, et al: The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest. 117:1884–1892. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Loberg RD, Day LL, Harwood J, et al: CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 8:578–586. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Lu Y, Cai Z, Galson DL, et al: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311–1318. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Roca H, Varsos Z and Pienta KJ: CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem. 283:25057–25073. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Ek S, Björck E, Högerkorp CM, et al: Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 118:2092–2097. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Murooka TT, Rahbar R and Fish EN: CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun. 387:381–386. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Barbieri F, Bajetto A, Stumm R, et al: Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res. 14:5022–5032. 2008. View Article : Google Scholar
21.	Singh RK and Lokeshwar BL: Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer. 8:572009. View Article : Google Scholar